Bridion growth trends

In the first quarter, sales of Merck’s (MRK) hospital acute care drug, Bridion, rose 25% YoY (year-over-year) on a reported basis and 30% on a CC (constant-currency) basis to $255 million. In fiscal 2018, Bridion revenue rose 30% YoY to $917 million on a reported and CC basis. In its first-quarter conference call, Merck stated that Bridion’s increasing use in US markets as a neuromuscular reversal agent in surgical procedures has been its driving force in fiscal 2019.

Gardasil and Bridion: Merck’s High-Growth Assets

Ready to put your morning scrolling to use? Sign up for Bagels & Stox, our witty take on the top market and investment news straight to your inbox! Whether you’re a serious investor or just want to be informed, Bagels & Stox will be your favorite email.

Gardasil/Gardasil 9

In the first quarter, sales of Merck’s human papillomavirus vaccine, Gardasil/Gardasil 9, rose 27% YoY on a reported basis and 31% YoY on CC basis to $838 million. In fiscal 2018, Gardasil/Gardasil 9 revenue rose 37% YoY on a reported basis and 36% YoY on a CC basis to $3.15 billion. Merck stated in its first-quarter press release that increased uptake due to its Chinese launch, gender-neutral vaccination in Europe, and public-sector purchases in Latin America drove demand for the vaccine in fiscal 2019.

V114 vaccine program

Merck expects the first data readout from its registrational Phase 3 program evaluating its pneumococcal conjugate vaccine, V114, in fiscal 2019. If approved by the FDA, the vaccine could be a solid revenue driver for Merck in future years. To learn about AbbVie’s key a growth drivers, read AbbVie’s Guidance for the Second Quarter of Fiscal 2019.

Latest articles

President Trump tweeted about his plans to meet with Apple (AAPL) CEO Tim Cook. It's possible that they could discuss Apple’s US manufacturing plans.

WeWork is gearing up for an IPO. On Wednesday, the company made its IPO filing with the SEC public and expects to garner $3.5 billion from its IPO.

After FCC Chairman Ajit Pai recommended the approval of the T-Mobile–Sprint merger, Representative David Cicilline urged the FCC to allow public comment.

Cresco Labs (CRLBF) is set to report its Q2 earnings on August 21 after the market closes. The company's stock fell 5.3% yesterday.

Cannabis stocks mostly traded in positive territory today. Supreme Cannabis (FIRE) and Aurora Cannabis (ACB) rose about 9.5% and 5.5%, respectively.

NVIDIA (NVDA) stock soared 6% in today’s trading session as its Q2 earnings for fiscal 2020 beat estimates. However, its guidance missed estimates.